CSIMarket
 
Inergetics Inc  (NRTI)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 298
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Inergetics Inc
Inergetics Inc is a biotechnology company that focuses on researching, developing, and marketing nutritional supplements. The company aims to improve the overall well-being of individuals through innovative products that support various health needs, including energy, weight management, and performance enhancement. Inergetics Inc emphasizes the use of natural ingredients and scientific research to provide high-quality supplements to consumers.


   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Affimed N V

The Deficit has enlarged further at the Affimed N V in financial fourth quarter of 2023

/>Affimed N.V., a leading clinical-stage immuno-oncology company, recently released its financial results for the fiscal year 2023. These results highlight a significant decline in revenue and an increased net loss per share compared to the previous year. However, despite the challenging financial performance, Affimed has also provided an update on the promising clinical response data for its AFM24-102 trial in treating EGFRwt NSCLC. This article will explore the potential impact of these financial results and the implications for Affimed's future.
Disastrous Financials:
In the fiscal fourth quarter of 2023, Affimed N.V. reported a disastrous financial performance, with revenue fading by 79.99% to $9.27 million and a net loss per share widening to $-7.94 from the corresponding quarter a year ago. The company's net deficit for the quarter amounted to $-118.651 million, surpassing the $-96.324 million deficit of the previous year.

Pds Biotechnology Corp

In the fiscal time-frame ending fourth quarter of 2023 operating deficit showed enhancement to $-18.821351 million, at the PDSB

The Major Pharmaceutical Preparations industry experts start to scrutinize the fourth quarter of 2023 earnings. Today those experts follow operating deficit of $-10.406961 million, from the PDSB, which hasn't specified any revenue thus far, for the respective October to December 31 2023 reporting period.

Chemomab Therapeutics Ltd

Among many companies, the CMMB disclosed also its fourth quarter of 2023 performance

While the October to December 31 2023 reporting season resumes, many companies have reported the earnings. In the thick of it, have been various constituents of the Major Pharmaceutical Preparations sector. As well as, today, CMMB disclosed operating deficit of $-25.459 million, for the most recent fiscal period.

Monopar Therapeutics Inc

Between many corporations, the MNPR issued as well the fourth quarter of 2023 numbers

Investors in the stock market have something to celebrate as the October to December 31, 2023 reporting cycle resumes. Numerous corporations, including those in the Major Pharmaceutical Preparations industry, have announced their earnings, and one company that stands out is Monopar Therapeutics Inc. (Nasdaq: MNPR).
Despite facing some challenges, Monopar Therapeutics has shown resilience and determination in its day-to-day operations, resulting in a significant improvement in its financial performance compared to the previous year. In the fourth quarter of 2023, the company reported an operating shortfall of $-1.911988 million, which is a clear improvement over the $-2.896 million reported in the same period of 2022.

Casi Pharmaceuticals Inc

Looking into fourth quarter of 2023 numbers, the Major Pharmaceutical Preparations company's saw a stunning -21.407 %, in revenue

Declining business caused an increase in deficit for the fiscal three months ending December 31 2023, Casi Pharmaceuticals Inc s' deficit per share inched up to $-2.02 from $-3.01 where Revenue went down by -21.407 % to $33.88 million from $43.11 million a year ago.






 

Inergetics Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Inergetics Inc does not provide revenue guidance.

Earnings Outlook
Inergetics Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com